Ocular Therapeutix

Ocular Therapeutix, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies for diseases and conditions of the eye. Its product pipeline includes Dextenza, OTX-TP, and OTX-TIC. The company was founded by Amarpreet S. Sawhney and Farhad Khosravi on September 12, 2006 and is headquartered in Bedford, MA.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Ocular Therapeutix reports strong Q4 performance and eyes pivotal trials

Ocular Therapeutix delivered a strong performance in Q4 2022, showcasing revenue growth and advancements in key product developments.
While facing financial challenges and the need for strategic partnerships, the company's solid cash position and product pipeline offer opportunities for future growth.
Investors should monitor Ocular Therapeutix's progress in pivotal trials, commercial expansion, and potential alliances to assess its long-term growth prospects.

Ocular Therapeutix progresses on OTX-TKI program and boosts sales

Ocular Therapeutix showcased advancements in its OTX-TKI program and DEXTENZA sales growth, while addressing financial performance.
Positive clinical trial updates and pricing strategy enhancements position the company for future growth.
Challenges include lack of operational spend guidance and uncertainties in study timelines, with opportunities in trial outcomes and market expansion.

Ocular Therapeutix reports record revenue, navigates pivotal trial funding

Ocular Therapeutix (OCUL) achieved record revenue with DEXTENZA and made significant progress in pipeline development.
While facing financial challenges and operational complexities, the company's strategic initiatives and leadership additions position it for future growth.
Advancements in trial designs, FDA interactions, and funding strategies offer avenues for enhancing product development and commercialization.

Ocular Therapeutix reports strong Q3 revenue growth and advances AMD treatment

Ocular Therapeutix's Q3 performance reflects revenue growth driven by DEXTENZA, with a focus on advancing wet AMD treatment through the OTX-TKI program.
While facing challenges in R&D expenses and trial enrollment criteria, the company is well-positioned with funding options and strategic partnerships.
Opportunities lie in expanding DEXTENZA's market presence, achieving pipeline milestones, and leveraging funding avenues for future growth and innovation.

Ocular Therapeutix excels in retinal focus, poised for leadership

Ocular Therapeutix is on a positive trajectory with advancements in key studies and a strong financial position. The company faces competition and regulatory challenges but has the potential to lead in retinal disease treatment with its innovative approach.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

BEDFORD, Mass.--(BUSINESS WIRE)---- $OCUL #OCUTX--Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, announced multiple scientific presentations at the American Academy of Ophthalmology (AAO) 2020 Virtual Annual Meeting being held November 13 -15, 2020. “We are presenting two posters and a paper at this year's American Academy of Ophthalmology (AAO) that continue to hig

Ocular Therapeutix™ To Present Data at the American Academy of Ophthalmology (AAO) 2020 Virtual Annual Meeting

Ocular Therapeutix (OCUL) delivered earnings and revenue surprises of 26.09% and 0.51%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Ocular Therapeutix (OCUL) Reports Q3 Loss, Tops Revenue Estimates (Revised)

Ocular Therapeutix, Inc. (OCUL) CEO Antony Mattessich on Q3 2020 Results - Earnings Call Transcript

BEDFORD, Mass.--(BUSINESS WIRE)---- $OCUL #OCUTX--Ocular Therapeutix™, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced financial results for the quarter ended September 30, 2020 and provided a business update. “It has been a productive quarter for Ocular Therapeutix with a number of key developments that we believe will drive significant long-term value,” said Antony Ma

Ocular Therapeutix™ Reports Third Quarter 2020 Financial Results and Business Update

BEDFORD, Mass.--(BUSINESS WIRE)---- $OCUL #OCUTX--Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that its application for the creation of a Category I Current Procedural Terminology (CPT) procedure code, presented at the October 2020 American Medical Association (AMA) CPT Editorial Panel (Panel) meeting, has been granted. The Panel has accepted the a

Ocular Therapeutix Announces Receipt of a Permanent Category I CPT Code from the American Medical Association for the Insertion of Intracanalicular Inserts

CASI Pharmaceuticals

Incyte

Zai Lab Ltd.

CStone Pharma out-licensed global rights (ex-China) for two immuno-oncology assets to US-based EQRx in a $1.3 billion agreement. CASI Pharma in-licensed China rights to a novel antibody checkpoint receptor inhibitor from Sweden's BioInvent in a $95 million deal.

Week In Review: CStone Out-Licenses Ex-China Rights To 2 Immunotherapies In $1.3 Billion Deal

BEDFORD, Mass.--(BUSINESS WIRE)---- $OCUL #OCUTX--Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced a license agreement and a collaboration with AffaMed Therapeutics for the development and commercialization of DEXTENZA® and OTX-TIC in Greater China, South Korea, and the ASEAN markets. DEXTENZA is currently approved in the U.S. for the treatment of post

Ocular Therapeutix™ and AffaMed Therapeutics Announce License Agreement and Collaboration for DEXTENZA® and OTX-TIC in Asia

Ocular Therapeutix (OCUL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Ocular Therapeutix (OCUL) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

BEDFORD, Mass.--(BUSINESS WIRE)---- $OCUL #OCUTX--Ocular Therapeutix™, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that it will report third quarter financial results on Thursday, November 5, 2020. Following distribution of the earnings release via wire services, the Ocular Therapeutix management team will host a live conference call and webcast at 4:30 p.m. Eastern

Ocular Therapeutix™ To Report Third Quarter 2020 Financial Results

As of late, it has definitely been a great time to be an investor in Ocular Therapeutix (OCUL).

Ocular Therapeutix's (OCUL) Shares March Higher, Can It Continue?

Ocular Therapeutix: Buy What 80% Of Patients Want

BEDFORD, Mass.--(BUSINESS WIRE)---- $OCUL #OCUTX--Ocular Therapeutix™, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced topline Phase 1 clinical trial results of OTX-CSI (cyclosporine intracanalicular insert) for the treatment of dry eye disease (DED). “The results of the Phase 1 clinical trial provide an early look at the safety, tolerability, durability, and potential

Ocular Therapeutix™ Announces Topline Phase 1 Clinical Trial Results of OTX-CSI

BEDFORD, Mass.--(BUSINESS WIRE)---- $OCUL #OCUTX--Ocular Therapeutix, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today reported preliminary, unaudited net product revenue for the third quarter ended September 30, 2020. The Company is reporting preliminary third quarter 2020 total net product revenue of $5.8 to 5.9 million, representing a greater than 250 % sequential increase over

Ocular Therapeutix Announces Preliminary Net Product Revenue of $5.8 Million to $5.9 Million for Third Quarter 2020, Representing Greater Than a 250% Increase Over the Previous Quarter

BEDFORD, Mass.--(BUSINESS WIRE)---- $OCUL #OCUTX--Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that it has granted a non-statutory stock option to purchase up to an aggregate of 350,000 shares of common stock of Ocular Therapeutix to a new employee, Philip C. Strassburger, as an inducement to his commencement of employment with Ocular. The award wa

Ocular Therapeutix Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

BEDFORD, Mass.--(BUSINESS WIRE)---- $OCUL #OCUTX--Ocular Therapeutix™, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that it has dosed the first patients in its Phase 2 clinical trial of OTX-CSI (cyclosporine intracanalicular insert) for the treatment of dry eye disease. “Having successfully completed the Phase 1 study, we are excited to have recently begun dosing pat

Ocular Therapeutix™ Announces First Patients Dosed in Phase 2 Clinical Trial of OTX-CSI for the Treatment of Dry Eye Disease

BEDFORD, Mass.--(BUSINESS WIRE)---- $OCUL #OCUTX--Ocular Therapeutix™, Inc.

Ocular Therapeutix™ Announces First Patient Dosed in Phase 3 Clinical Trial of DEXTENZA® for the Treatment of Post-Surgical Ocular Inflammation and Pain in Children

BEDFORD, Mass.--(BUSINESS WIRE)---- $OCUL #OCUTX--Ocular Therapeutix, Inc.

Ocular Therapeutix™ Announces Successful Resolution of FDA Warning Letter Related to ReSure® Sealant

Ocular Therapeutix Announces Third Medicare Administrative Contractor to Establish New Published Physician Fee Schedule for Administration of Intracanalicular Inserts

Ocular - Small-Cap Pharmaceutical Growth Story

Ocular Therapeutix, Inc. (OCUL) CEO Antony Mattessich on Q2 2020 Results - Earnings Call Transcript

Ocular Therapeutix (OCUL) delivered earnings and revenue surprises of -6.25% and -1.94%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Ocular Therapeutix (OCUL) Reports Q2 Loss, Misses Revenue Estimates

Shares of Ocular Therapeutix (NASDAQ:OCUL) moved higher by 1% in pre-market trading after the company reported Q2 results.

Ocular Therapeutix: Q2 Earnings Insights

Ocular Therapeutix™ Reports Second Quarter 2020 Financial Results and Business Update

Ocular Therapeutix™ To Report Second Quarter 2020 Financial Results

Ocular Therapeutix (OCUL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

News for Ocular Therapeutix Stock (OCUL)